82 FR 28081 - National Center for Advancing Translational Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 117 (June 20, 2017)

Page Range		28081-28082
FR Document		2017-12752

Federal Register, Volume 82 Issue 117 (Tuesday, June 20, 2017)

[Federal Register Volume 82, Number 117 (Tuesday, June 20, 2017)]
[Notices]
[Pages 28081-28082]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-12752]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; CTSA Program Data to Health 
Coordinating Center (U24).
    Date: July 17, 2017.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, One Democracy Plaza, Room 
206, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone 
Conference Call).
    Contact Person: Victor Henriquez, Ph.D., Scientific Review 
Officer, Office of Scientific Director, National Center for 
Advancing Translational Sciences (NCATS), National Institutes of 
Health, 6701 Democracy Blvd., Democracy 1, Room 1080, Bethesda, MD 
20892-4878, 301-451-2405, [email protected].

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; NCATS Pilot Program for 
Collaborative Drug Discovery Research using Bioprinted Skin Tissue 
(U18): RFA-TR-17-007.
    Date: July 19, 2017.
    Time: 1:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, One Democracy Plaza, Room 
1087, 6701 Democracy Boulevard, Bethesda, MD 20892 (Telephone 
Conference Call).
    Contact Person: Rahat (Rani) Khan, Ph.D., Scientific Review 
Officer, Office of Scientific Review, National Center for Advancing 
Translational Sciences, 6701 Democracy Blvd., Rm 1078, Bethesda, MD 
20892, 301-894-7319, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)


[[Page 28082]]


    Dated: June 14, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-12752 Filed 6-19-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 117 / Tuesday, June 20, 2017 / Notices 28081

Name of Committee: Center for Scientific Health, 6701 Rockledge Drive, Room 4187, DEPARTMENT OF HEALTH AND
Review Special Emphasis Panel; Small Bethesda, MD 20892, 301–537–9986, HUMAN SERVICES
Business: Cardiovascular Sciences. macarthurlh@csr.nih.gov.
Date: July 13–14, 2017. National Institutes of Health
Name of Committee: Center for Scientific
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant Review Special Emphasis Panel; Member
Conflict: Molecular Neurogenetics. National Center for Advancing
applications.
Place: Hotel Solamar, 435 6th Avenue, San Date: July 13, 2017. Translational Sciences; Notice of
Diego, CA 92101. Time: 2:00 p.m. to 4:00 p.m. Closed Meetings
Contact Person: Margaret Chandler, Ph.D., Agenda: To review and evaluate grant Pursuant to section 10(d) of the
Scientific Review Officer, Center for applications. Federal Advisory Committee Act, as
Scientific Review, National Institutes of Place: National Institutes of Health, 6701
Health, 6701 Rockledge Drive, Room 4126, amended (5 U.S.C. App.), notice is
Rockledge Drive, Bethesda, MD 20892 hereby given of the following meetings.
MSC 7814, Bethesda, MD 20892, (301)435– (Telephone Conference Call).
1743, margaret.chandler@nih.gov. The meetings will be closed to the
Contact Person: Paek-Gyu Lee, Ph.D., public in accordance with the
Name of Committee: AIDS and Related Scientific Review Officer, Center for
Research Integrated Review Group; HIV/ provisions set forth in sections
Scientific Review, National Institutes of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
AIDS Vaccines Study Section.
Health, 6701 Rockledge Drive, Room 4201, as amended. The grant applications and
Date: July 13, 2017.
Time: 8:00 a.m. to 6:00 p.m. MSC 7812, Bethesda, MD 20892, (301) 613– the discussions could disclose
Agenda: To review and evaluate grant 2064, leepg@csr.nih.gov. confidential trade secrets or commercial
applications. Name of Committee: Center for Scientific property such as patentable material,
Place: The Fairmont Washington, DC, 2401 Review Special Emphasis Panel; Member and personal information concerning
M Street NW., Washington, DC 20037. Conflict: Receptors, Channels and Circuits. individuals associated with the grant
Contact Person: Barna Dey, Ph.D., Date: July 13, 2017.
Scientific Review Officer, Center for applications, the disclosure of which
Time: 12:00 p.m. to 3:30 p.m. would constitute a clearly unwarranted
Scientific Review, National Institutes of
Agenda: To review and evaluate grant invasion of personal privacy.
Health, 6701 Rockledge Drive, Room 3184,
Bethesda, MD 20892, 301–435–0000, applications.
Place: National Institutes of Health, 6701 Name of Committee: National Center for
bdey@mil.nih.gov. Advancing Translational Sciences Special
Rockledge Drive, Bethesda, MD 20892
Name of Committee: Center for Scientific Emphasis Panel; CTSA Program Data to
Review Special Emphasis Panel; Small (Telephone Conference Call). Health Coordinating Center (U24).
Business: Neuroscience Assay, Diagnostics Contact Person: Afia Sultana, Ph.D., Date: July 17, 2017.
and Animal Model Development. Scientific Review Officer, National Institutes Time: 12:00 p.m. to 4:00 p.m.
Date: July 13, 2017. of Health, Center for Scientific Review, 6701 Agenda: To review and evaluate grant
Time: 8:00 a.m. to 7:00 p.m. Rockledge Drive, Bethesda, MD 20892, (301) applications.
Agenda: To review and evaluate grant 827–7083, sultanaa@mail.nih.gov. Place: National Institutes of Health, One
applications. Name of Committee: Center for Scientific Democracy Plaza, Room 206, 6701
Place: The St. Regis Washington DC, 923 Democracy Boulevard, Bethesda, MD 20892
Review Special Emphasis Panel; Member
16th Street NW., Washington, DC 20006. (Telephone Conference Call).
Conflict: Health Services Organization and
Contact Person: Susan Gillmor, Ph.D., Contact Person: Victor Henriquez, Ph.D.,
Scientific Review Officer, National Institutes Delivery. Scientific Review Officer, Office of Scientific
of Health, Center for Scientific Review, 6701 Date: July 13, 2017. Director, National Center for Advancing
Rockledge Drive, Bethesda, MD 20892, 301– Time: 12:00 p.m. to 3:00 p.m. Translational Sciences (NCATS), National
435–1730, susan.gillmor@nih.gov. Agenda: To review and evaluate grant Institutes of Health, 6701 Democracy Blvd.,
Name of Committee: Center for Scientific applications. Democracy 1, Room 1080, Bethesda, MD
Review Special Emphasis Panel; Place: National Institutes of Health, 6701 20892–4878, 301–451–2405, henriquv@
Biochemistry and Biophysics of Biological Rockledge Drive, Bethesda, MD 20892 mail.nih.gov.
Macromolecules Fellowship Applications. (Telephone Conference Call). Name of Committee: National Center for
Date: July 13, 2017. Contact Person: Yvonne Owens Ferguson, Advancing Translational Sciences Special
Time: 8:00 a.m. to 7:00 p.m. Ph.D., Scientific Review Officer, Center for Emphasis Panel; NCATS Pilot Program for
Agenda: To review and evaluate grant Scientific Review, National Institutes of Collaborative Drug Discovery Research using
applications. Health, 6701 Rockledge Drive Room 3139, Bioprinted Skin Tissue (U18): RFA–TR–17–
Place: Courtyard by Marriott, 5520 007.
Bethesda, MD 20892, 301–827–3689,
Wisconsin Avenue, Chevy Chase, MD 20815. Date: July 19, 2017.
Contact Person: Sudha Veeraraghavan, fergusonyo@csr.nih.gov.
Time: 1:00 p.m. to 4:30 p.m.
Ph.D., Scientific Review Officer, Center for (Catalogue of Federal Domestic Assistance Agenda: To review and evaluate grant
Scientific Review, National Institutes of Program Nos. 93.306, Comparative Medicine; applications.
Health, 6701 Rockledge Drive, Bethesda, MD 93.333, Clinical Research, 93.306, 93.333, Place: National Institutes of Health, One
20892, 301–435–1504, 93.337, 93.393–93.396, 93.837–93.844, Democracy Plaza, Room 1087, 6701
sudha.veeraraghavan@nih.gov. 93.846–93.878, 93.892, 93.893, National Democracy Boulevard, Bethesda, MD 20892
Name of Committee: Center for Scientific Institutes of Health, HHS) (Telephone Conference Call).
Review Special Emphasis Panel; The Blood- Contact Person: Rahat (Rani) Khan, Ph.D.,
Brain Barrier, Neurovascular Systems and Dated: June 14, 2017. Scientific Review Officer, Office of Scientific
CNS Therapeutics. David Clary, Review, National Center for Advancing
Date: July 13, 2017. Translational Sciences, 6701 Democracy
Program Analyst, Office of Federal Advisory
Time: 10:00 a.m. to 3:00 p.m. Blvd., Rm 1078, Bethesda, MD 20892, 301–
sradovich on DSK3GMQ082PROD with NOTICES

Committee Policy.
Agenda: To review and evaluate grant 894–7319, khanr2@csr.nih.gov.
[FR Doc. 2017–12750 Filed 6–19–17; 8:45 am]
applications. (Catalogue of Federal Domestic Assistance
Place: National Institutes of Health, 6701 BILLING CODE 4140–01–P Program Nos. 93.859, Pharmacology,
Rockledge Drive, Bethesda, MD 20892 Physiology, and Biological Chemistry
(Telephone Conference Call). Research; 93.350, B—Cooperative
Contact Person: Linda MacArthur, Ph.D., Agreements; 93.859, Biomedical Research
Scientific Review Officer, Center for and Research Training, National Institutes of
Scientific Review, National Institutes of Health, HHS)

VerDate Sep<11>2014 18:01 Jun 19, 2017 Jkt 241001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\20JNN1.SGM 20JNN1

28082 Federal Register / Vol. 82, No. 117 / Tuesday, June 20, 2017 / Notices

Dated: June 14, 2017. tribes and pharmaceutical and medical evaluation, collaboration, challenges,
David Clary, communities to understand the risks of and health disparities. Information from
Program Analyst, Office of Federal Advisory overprescribing to youth age 12–17 and these interviews will help inform SPF-
Committee Policy. adults 18 years of age and older. The Rx cross-site evaluation reports and will
[FR Doc. 2017–12752 Filed 6–19–17; 8:45 am] program also aims to enhance capacity help identify lessons learned and
BILLING CODE 4140–01–P for, and access to, Prescription Drug success stories from grantees’ SPF-Rx
Monitoring Program (PDMP) data for programs.
prevention purposes. • Grantee- and Community-Level
DEPARTMENT OF HEALTH AND The SPF-Rx program aims to address Outcomes Modules to collect data on
HUMAN SERVICES SAMHSA’s priorities on prevention and key SPF-Rx program outcomes,
reduction of prescription drug and illicit including opioid misuse and abuse,
Substance Abuse and Mental Health opioid misuse and abuse. Its indicators opioid overdoses, and opioid
Services Administration of success are reductions in opioid prescribing patterns. Grantees will
overdoses and the incorporation of provide outcomes data at the grantee
Agency Information Collection PDMP data into needs assessments and level for their state, tribal area, or
Activities: Submission for OMB strategic plans. Data collected through jurisdiction, as well as at the
Review; Comment Request the tools described in this statement community level for each of their
Periodically, the Substance Abuse and will be used for the national cross-site subrecipient communities.
Mental Health Services Administration evaluation of SAMHSA’s SPF-Rx • Substitute Data Source Request to
(SAMHSA) will publish a summary of program. This package covers continued allow grantees to request permission
information collection requests under data collection through 2020, as the from SAMHSA to use ‘‘substitute
OMB review, in compliance with the evaluation is expected to continue measures’’ for their outcomes data—that
Paperwork Reduction Act (44 U.S.C. through at least that time; however, the is, measures that differ from a list of
Chapter 35). To request a copy of these Program Evaluation for Prevention preapproved outcomes measures.
documents, call the SAMHSA Reports Contract (PEP–C) is scheduled to • Annual Implementation Instrument
Clearance Officer at (240) 276–1243. conduct a national cross-site evaluation to collect data completed by grantees
of SPF-Rx through September 2018. The and subrecipient community PDs. Data
Project: Strategic Prevention PEP–C team will systematically collect collected from the survey will be used
Framework for Prescription Drugs and maintain an Annual to monitor subrecipient and state, tribal
(SPF-Rx)—New Implementation Instrument (AII) and entity, or jurisdiction performance and
The Substance Abuse and Mental outcomes data submitted by SPF-Rx to evaluate the effectiveness of the SPF-
Health Services Administration grantees through the online PEP–C Rx program across states, tribal entities,
(SAMHSA)’s Center for Substance Management Reporting Tool (MRT). and jurisdictions.
Abuse Prevention (CSAP) aims to SAMHSA is requesting approval for • Grantee Interview to collect
conduct a cross-site evaluation of the data collection for the SPF-Rx cross-site semistructured telephone interview data
Strategic Prevention Framework for evaluation with the following four to gather more in-depth information on
Prescription Drug (SPF-Rx) program. instruments: organizational infrastructure, use of
The SPF-Rx program is designed to • Grantee Interview to obtain the PDMP data, collaboration, leveraging of
address nonmedical use of prescription perspective of the implementing Project funds and resources, and evaluation
drugs (as well as) opioid overdoses by Directors (PDs) or their staff on activities
raising awareness about the dangers of important topics, including • Evaluation Plan to allow grantees to
sharing medications and by working infrastructure and capacity, outline their local evaluation plan.
with pharmaceutical and medical collaboration, leveraging funding and Sections include goals and objectives,
communities. The SPF-Rx program aims resources, criteria and use of evidence- performance measures, data analysis
to promote collaboration between states/ informed interventions, monitoring and plan, and reporting plan.

ANNUALIZED DATA COLLECTION BURDEN
Responses Total
Number of Hours per Total burden
Instrument per number of
respondents response hours
respondent responses

Grantee-Level Outcomes Module ........................................ 25 1 25 3 75
Community-Level Outcomes Module ................................... 25 1 25 3 75
Substitute Data Request Form ............................................ 12 1 12 1 12
Annual Implementation Instrument ...................................... 100 1 100 2.3 230
Grantee-Level Interview ....................................................... 17 1 17 1.5 25.5
Evaluation Plan .................................................................... 25 1 25 8 200

Overall Total ................................................................. 100 ........................ 204 ........................ 618
Note. Annualized Data Collection Burden captures the average number of respondents and responses, burden hours, and respondent cost
over the 3 years (FY2018–FY2020).
sradovich on DSK3GMQ082PROD with NOTICES

Written comments and and Regulatory Affairs, Office of through the U.S. Postal Service,
recommendations concerning the Management and Budget (OMB). To commenters are encouraged to submit
proposed information collection should ensure timely receipt of comments, and their comments to OMB via email to:
be sent by July 20, 2017 to the SAMHSA to avoid potential delays in OMB’s OIRA_Submission@omb.eop.gov.
Desk Officer at the Office of Information receipt and processing of mail sent Although commenters are encouraged to

VerDate Sep<11>2014 18:01 Jun 19, 2017 Jkt 241001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\20JNN1.SGM 20JNN1

Document Created: 2017-06-20 02:21:27
Document Modified: 2017-06-20 02:21:27

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		July 17, 2017.
FR Citation		82 FR 28081

82 FR 28081 - National Center for Advancing Translational Sciences; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 117 (June 20, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health